Skip to main content

Baker Julian's Form 4 filing

Kodiak Sciences Inc.KOD ยท filed Sep 30, 2026

Accession no.
0001193125-26-409116
Filed
Sep 30, 2026, 4:29 PM ET
Trade date
Sep 28, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 30 non-derivative transactions. Open-market purchases total $58.6M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Baker JulianCIK 0001087939Director, 10% Owner
Baker FelixCIK 0001087940Director, 10% Owner
Baker Bros. Advisors LPCIK 0001263508Director, 10% Owner
Baker Brothers Life Sciences LPCIK 0001363364Director, 10% Owner
667, L.P.CIK 0001551139Director, 10% Owner
Baker Bros. Advisors (GP) LLCCIK 0001580575Director, 10% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 28, 2026Common StockPPurchaseAcquired+856$61.21F1+$52,396.11,561,270Indirect
Sep 28, 2026Common StockPPurchaseAcquired+14,344$61.21F1+$878,001.9818,373,116Indirect
Sep 28, 2026Common StockPPurchaseAcquired+2,666$61.63F6+$164,292.781,563,936Indirect
Sep 28, 2026Common StockPPurchaseAcquired+44,690$61.63F6+$2,754,030.1918,417,806Indirect
Sep 28, 2026Common StockPPurchaseAcquired+243$62.96F7+$15,299.841,564,179Indirect
Sep 28, 2026Common StockPPurchaseAcquired+4,067$62.96F7+$256,067.6718,421,873Indirect
Sep 28, 2026Common StockPPurchaseAcquired+479$64.43F8+$30,860.821,564,658Indirect
Sep 28, 2026Common StockPPurchaseAcquired+8,021$64.43F8+$516,773.7818,429,894Indirect
Sep 28, 2026Common StockPPurchaseAcquired+321$67.10F9+$21,538.041,564,979Indirect
Sep 28, 2026Common StockPPurchaseAcquired+5,382$67.10F9+$361,114.4418,435,276Indirect
Sep 28, 2026Common StockPPurchaseAcquired+154$68.37F10+$10,529.531,565,133Indirect
Sep 28, 2026Common StockPPurchaseAcquired+2,585$68.37F10+$176,745.7618,437,861Indirect
Sep 28, 2026Common StockPPurchaseAcquired+2,331$68.96F11+$160,740.631,567,464Indirect
Sep 28, 2026Common StockPPurchaseAcquired+39,066$68.96F11+$2,693,905.4118,476,927Indirect
Sep 28, 2026Common StockPPurchaseAcquired+1,056$71.48F12+$75,487.421,568,520Indirect
Sep 28, 2026Common StockPPurchaseAcquired+17,698$71.48F12+$1,265,129.1418,494,625Indirect
Sep 28, 2026Common StockPPurchaseAcquired+16,641$72.39F13+$1,204,597.061,585,161Indirect
Sep 28, 2026Common StockPPurchaseAcquired+278,978$72.39F13+$20,194,464.1818,773,603Indirect
Sep 28, 2026Common StockPPurchaseAcquired+4,696$73.08F14+$343,172.881,589,857Indirect
Sep 28, 2026Common StockPPurchaseAcquired+78,726$73.08F14+$5,753,115.0118,852,329Indirect
Sep 28, 2026Common StockPPurchaseAcquired+4,577$73.97F15+$338,554.281,594,434Indirect
Sep 28, 2026Common StockPPurchaseAcquired+76,723$73.97F15+$5,675,092.918,929,052Indirect
Sep 28, 2026Common StockPPurchaseAcquired+1,924$75.52F16+$145,291.051,596,358Indirect
Sep 28, 2026Common StockPPurchaseAcquired+32,261$75.52F16+$2,436,192.6418,961,313Indirect
Sep 28, 2026Common StockPPurchaseAcquired+3,681$76.35F17+$281,025.951,600,039Indirect
Sep 28, 2026Common StockPPurchaseAcquired+61,700$76.35F17+$4,710,486.519,023,013Indirect
Sep 28, 2026Common StockPPurchaseAcquired+2,884$77.43F18+$223,312.161,602,923Indirect
Sep 28, 2026Common StockPPurchaseAcquired+48,350$77.43F18+$3,743,808.1919,071,363Indirect
Sep 28, 2026Common StockPPurchaseAcquired+2,969$78.57F19+$233,268.691,605,892Indirect
Sep 28, 2026Common StockPPurchaseAcquired+49,771$78.57F19+$3,910,412.9119,121,134Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported in Column 4 is a weighted average price. These shares of common stock ("Common Stock") of Kodiak Sciences Inc. (the "Issuer") were traded by 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") in multiple transactions at prices ranging from $60.50 to $61.42, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "Staff"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $61.44 to $62.43, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $62.48 to $63.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F8

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $63.72 to $64.66, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F9

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $66.86 to $67.23, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $68.28 to $68.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F11

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $68.65 to $69.52, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F12

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $70.80 to $71.76, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F13

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $71.77 to $72.765, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F14

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $72.77 to $73.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F15

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $73.88 to $74.86, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F16

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $74.88 to $75.86, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F17

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $75.88 to $76.88, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F18

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $76.94 to $77.88, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

F19

The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $77.92 to $78.91, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

Referenced by the price of 2 transactions in Table I.

Remarks

Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC, the sole general partner of Baker Bros. Advisors LP, is a director of Kodiak Sciences Inc. (the "Issuer"). By virtue of their representation on the board of directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons other than Felix J. Baker are deemed directors by deputization of the Issuer. This is the first of three Forms 4 reporting changes in beneficial ownership. Due to space limitations in Form 4 we are thus filing these three Forms 4.

Read the full filing on SEC EDGAR (opens in a new tab)